v/LinkedIn
May 25, 2025, 10:39
Marko Skelin: Our New Meta-Analysis on Immunotherapy’s Role in Treating Mesothelioma
Marko Skelin, Assistant Professor at University of Rijeka, shared an article on LinkedIn:
“New Insights on Immunotherapy in Mesothelioma from Our Latest Research.
We (Mirko Grubor, Ivan Krečak, Bruna Perkov, Marko Skelin) are excited to share our new meta-analysis, published in the Journal of Chemotherapy, diving into immunotherapy’s role in treating mesothelioma.
After analyzing 7 clinical trials with 2,549 patients, here’s what we found:
Immunotherapy significantly improves overall survival (OS) with a pooled hazard ratio of 0.78 (P=0.0005), a promising step forward for patient outcomes.
Graph B: Surprisingly, no meaningful link between OS and objective response rate (ORR) (r=-0.23, P=0.66). This challenges the reliance on ORR as a primary measure in early drug development trials in this setting, and opens up new questions for exploration.
Graph A: A striking correlation between OS and progression-free survival (PFS) (r=0.86, P=0.01). This suggests PFS could serve as a reliable endpoint in future early drug development studies, potentially speeding up trial timelines.”
Immunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR.
Authors: Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, and Mirko Grubor.
You can read the full article on Journal of National Library of Medicine.
More posts featuring Mesothelioma.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 25, 2025, 14:10
May 25, 2025, 13:47
May 25, 2025, 13:33
May 25, 2025, 11:41
May 25, 2025, 11:24
May 25, 2025, 11:12